Diverse mass spectrometric instruments have been used to provide data for accurate mass and retention time (AMT) tag proteomics analyses, including ion trap, quadrupole time-of-flight, and Fourier transform mass spectrometry (FTMS). An important attribute of these instruments, beside mass accuracy, is their spectral resolution. In fact, the ability to separate peaks with close m/z values is likely to play a major role in enabling species identification and matching in analyses of very complex proteomics samples. In FTMS, resolution is directly proportional to the detection period and can therefore be easily tuned. We took advantage of this feature to investigate the effect of resolution on species identification and matching in an AMT tag experiment. Using an Arabidopsis thaliana chloroplast protein extract as prototypical 'real-life' sample, we have compared the number of detected features, the optimal mass tolerance for species matching, the number of matched species and the false discovery rate obtained at various resolution settings. It appears that while the total number of matches is not significantly affected by a reduction of resolution in the range investigated, the confidence level of identifications significantly drops as evidenced by the estimated false discovery rate.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/rcm.3447 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Siderophore Synthesis Ability of the Nitrogen-Fixing Bacterium (NFB) GXGL-4A is Regulated at the Transcriptional Level by a Transcriptional Factor (trX) and an Aminomethyltransferase-Encoding Gene (amt).
Curr Microbiol
October 2022
Department of Resources and Environment, School of Agriculture and Biology, Shanghai Jiao Tong University, Shanghai, 200240, China.
Kosakonia radicincitans GXGL-4A, a gram-negative nitrogen-fixing (NF) bacterial strain is coated with a thick capsulatus on the surface of cell wall, which becomes a physical barrier for exogenous DNA to enter the cell, so the operation of genetic transformation is difficult. In this study, an optimized Tn5 transposon mutagenesis system was established by using a high osmotic HO-1 medium combined with the electroporation transformation. Eventually, a mutant library containing a total of 1633 Tn5 insertional mutants were established.
View Article and Find Full Text PDFContribution of Common Genetic Variants to Risk of Early-Onset Ischemic Stroke.
Neurology
October 2022
From the Division of Endocrinology (T.J., H.X., B.J.G, B.D.M., K.A.R., J.A.P., P.F.M.), Diabetes and Nutrition, Department of Neurology (J.W.C., N.S.F., H.L., S.J.K.), Division of Rheumatology and Clinical Immunology (M.C.H.), Department of Medicine, Department of Epidemiology and Public Health (M.C.H.), and Institute for Genome Sciences (T.D.O.C.), University of Maryland School of Medicine; VA Maryland Health Care System (J.W.C.); Centre for Medical Informatics (K.R., C.L.M.S.), Usher Institute, University of Edinburgh, United Kingdom; Institute of Biomedicine (T.M.S., C.J.), Department of Laboratory Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden; Department of Neurology (L.T., J.P., D.S., T.T.), Helsinki University Hospital and University of Helsinki, Finland; Department of Molecular and Functional Genomics (V.A., J.L., R.Z.), Geisinger Health System, Danville, PA; LabEx DISTALZ-U1167 (P.A.), RID-AGE-Risk Factors and Molecular Determinants of Aging-Related Diseases, University of Lille; Inserm U1167 (P.A.), Lille; Centre Hospitalier Universitaire Lille (P.A.); Institut Pasteur de Lille (P.A.), France; Department of Epidemiology (N.D.A., M.R.I.), University of Alabama at Birmingham; School of Medicine and Public Health (J.A., E.H.), University of Newcastle and Hunter Medical Research Institute, Australia; Stroke Research Group (S.B., H.S.M.), Department of Clinical Neurosciences, British Heart Foundation Cardiovascular Epidemiology Unit (A.B., J.D.), Department of Public Health and Primary Care, British Heart Foundation Centre of Research Excellence (A.B., J.D.), National Institute for Health Research Blood and Transplant Research Unit in Donor Health and Genomics (A.B., J.D.), University of Cambridge (A.B., J.D.), United Kingdom; Department of Neurology (Q.R.B.), University of British Columbia, Vancouver, Canada; Department of Cerebrovascular Diseases (G.B.B.), Fondazione IRCCS Istituto Neurologico "Carlo Besta," Milan, Italy; Health Data Research UK Cambridge (A.B., J.D.); Wellcome Genome Campus (A.B., J.D.), Cambridge, United Kingdom; Stroke Pharmacogenomics and Genetics group (J.C.-M., I.F.-C., N.P.T.-A.), Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain; MRC Population Health Research Unit (Z.C., R.G.W.), Nuffield Department of Population Health, University of Oxford, United Kingdom; Nuffield Department of Clinical Neurosciences (P.M.R.), University of Oxford, United Kingdom; DBCVS Research Institute (M.C., G.P.), Department of Pathology and Molecular Medicine, Population Health Research Institute, McMaster University; Thrombosis & Atherosclerosis Research Institute (TaARI) (M.C., G.P.), Hamilton, Ontario, Canada; Departments of Neurology (J.-M.L.) and Psychiatry (C.C.), Washington University School of Medicine, St. Louis, MO; Department of Medicine and Laboratory for Clinical Biochemistry Research (J.P.D.), Department of Medicine, (M.C.), University of Vermont Larner College of Medicine, Burlington, VT; Department of Human Genetics (J.D.), Wellcome Sanger Institute, Hinxton, United Kingdom; University of Bordeaux (S.D., D.-A.T.), Inserm, Bordeux Population Health Research Center, UMR 1219; Department of Neurology (S.D.), Institute for Neurodegenerative Disease, Bordeaux University Hospital, France; Quantitative Medicine and Systems Biology Division (D.J.D.), Translational Genomics Research Institute, An Affiliate of City of Hope, Phoenix, AZ; Laboratory for Clinical Biochemistry Research (J.P.D.), Department of Clinical Sciences (G.E., J.A.S., M.S., D.R.W.), Malmö and Department of Clinical Sciences (A.I., M.S., A.G.L.), Neurology, Lund, Lund University, Sweden; Department of Neurology (C.E., R.S.), Medical University Graz, Austria; Survey Research Center (J.D.F.), Institute for Social Research, University of Michigan, Ann Arbor; Stroke Pharmacogenomics and Genetics (I.F.-C.), Fundacio Docència i Recerca MutuaTerrassa, Spain; Unit of Molecular Epidemiology (C.G.), Institute of Epidemiology (C.G., A.P.), Helmholtz Zentrum München German Research Center for Environmental Health, Neuherberg; Klinik und Poliklinik für Neurologie (A.-K.G.), Kopf- und Neurozentrum, Universitätsklinikum Hamburg-Eppendorf, Germany; Neuroscience Institute (R.P.G., L.R.P.), Saint Francis Medical Center, Trenton, NJ; Department for Biostatistics and Clinical Epidemiology (U.G., ), Charité-University Medical Centre, Berlin, Germany; National Institute for Health and Welfare (A.S.H., V.S.), Helsinki, Finland; Departments of Emergency Medicine and Neurology (L.H.), Washington University School of Medicine, St. Louis, MO; Division of Women's Health (K.R.), Department of Medicine and Department of Neurology (C.D.A.), Brigham and Women's Hospital, Harvard Medical School; Department of Epidemiology (J.H.), Harvard T.H. Chan School of Public Health, Boston, MA; Department of Neurology and Rehabilitation Medicine (A.I.), Skane University Hospital, Lund, Sweden; Division of Endocrinology (R.D.J.), Diabetes and Metabolism, Department of Internal Medicine and the Center for Clinical and Translational Science, The Ohio State University, Columbus; Department of Neurology (M.A.J., A.M.T., F.E.d.L.), Radboud University Medical Center, Donders Medical Center for Neuroscience, Nijmegen, the Netherlands; Department of Genetics, Microbiology and Statistics (R.R.J.), Institute of Biomedicine (IBUB), University of Barcelona; Institut de Recerca Sant Joan de Déu (R.R.J.), Esplugues de Llobregat; Centro de investigación biomédica en red (CIBERER) (R.R.J.); Neurovascular Research Group (NEUVAS) (J.J.-C.), Neurology Department, Institut Hospital del Mar d'Investigacio Medica, Universitat Autonoma de Barcelona, Spain; Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics (J.A.J., C.W.M.), University of Florida, College of Pharmacy; Division of Cardiovascular Medicine (J.A.J.), College of Medicine, University of Florida, Gainesville; Laboratory of Complex Trait Genomics (Y.K.), Graduate School of Frontier Sciences and Department of Cancer Biology (M.K.), Institute of Medical Science, The University of Tokyo, Japan; Department of Epidemiology (S.L.R.K.), School of Public Health, University of Michigan, Ann Arbor; Department of Cancer Biology (M.K.), RIKEN Center for Integrative Medical Sciences (M.K., C.T.), Yokohama, Japan; Department of Medicine (L.L.), University of Colorado Denver, Anschutz Medical Campus, Aurora, CO; Department of Neurosciences, Experimental Neurology (R.L.), VIB Center, For Brain & Disease Research, KU Leuven-University of Leuven; Department of Neurology (R.L.), University Hospitals Leuven, Belgium; John Hunter Hospital (C.R.L.), Hunter Medical Research Institute and University of Newcastle, Newcastle, Australia and Priority Research Centre for Stroke & Brain Injury, University of Newcastle, NSW, Australia; Peking University Health Science Center (L.L.), Department of Epidemiology and Biostatistics, Peking University, Beijing, China; Department of Neurology (S.L., J.F.M., O.A.R.), Mayo Clinic, Jacksonville, FL; Faculty of Health (J.M.), School of Nursing and Midwifery, University of Technology Sydney, NSW, Australia; Department of Neurology (T.M.), Helsinki University Central Hospital, Helsinki, Finland; Institute of Genetic Epidemiology (M.M.-N.), Helmholtz Zentrum München-German Research Center for Environmental Health, Neuherberg; Institute of Medical Biostatistics, Epidemiology and Informatics (IMBEI), University Medical Center, Johannes Gutenberg University Mainz, Germany; Department of Medicine I, Ludwig-Maximilians University Munich, Germany; Department of Medicine (C.C.H.) University of Maryland School of Medicine, Baltimore, MD; Health Research Board Clinical Research Facility (M.O.D.), Geata an Eolais, National University of Ireland, Galway; Department of Neurology (J.P., A.S.), Jagiellonian University, Krakow, Poland; Institute for Medical Information Sciences (A.P.), Biometry and Epidemiology, Ludwig-Maximilians-University, Munich, Germany; Department of Epidemiology (D.R.), Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD; Psychiatric Genetics Unit (M.R., C.S.-M.), Group of Psychiatry, Mental Health and Addiction, Vall d'Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona; Department of Psychiatry (C.S.-M.), Hospital Universitari Vall d'Hebron, Barcelona; Biomedical Network Research Centre on Mental Health (CIBERSAM) (M.R.), Instituto de Salud Carlos III, Madrid; Department of Genetics (M.R.), Microbiology, and Statistics, Faculty of Biology, Universitat de Barcelona, Spain; McCance Center for Brain Health (J.R., C.D.A.), Massachusetts General Hospital; Center for Genomic Medicine (J.R.), MGH; Department of Neurology (J.R.), MGH, Boston; Program in Medical and Population Genetics (J.R.), Broad Institute, Cambridge, MA; Department of Neurology and Evelin F. McKnight Brain Institute (T.R., R.L.S.), Miller School of Medicine, University of Miami, FL; Institute of Cardiovascular Research (P.S.), Royal Holloway University of London, and Ashford and St. Peters Hospital (P.S.), Surrey, United Kingdom; Group Health Research Institute (N.L.S.), Group Health Cooperative; Department of Epidemiology (N.L.S.), University of Washington; Seattle Epidemiologic Research and Information Center (N.L.S.), VA Office of Research and Development, Seattle, WA; Department of Epidemiology and Population Health (S.W.-S.), Albert Einstein College of Medicine, New York; BHF Data Science Centre (C.L.S.), Health Data Research UK, London, United Kingdom; Department of Neurology (T.T.) and Department of Clinical Genetics and Genomics (C.J.), Region Vastra Gotaland, Sahlgrenska University Hospital; Department of Clinical Neuroscience (T.T.), Institute of Neurosciences and Physiology, Sahlgrenska Academy at University of Gothenburg, Sweden; Stroke Theme (V.T.), Florey Institute of Neuroscience and Mental Health, University of Melbourne; Department of Neurology (V.T.), Austin Health, Heidelberg, Victoria, Australia; Department of Neurology (J.H.V.), University Medical Center Utrecht Brain Center, Utrecht University, the Netherlands; Department of Neurology and Rehabilitation Medicine (D.W.), University of Cincinnati College of Medicine, OH; Departments of Neurology and Public Health Sciences (B.B.W.), University of Virginia School of Medicine, Charlottesville; Section of Neurology (A.G.L.), Skåne University Hospital, Lund, Sweden; Program in Medical and Population Genetics (C.D.A.), Broad Institute of MIT and Harvard, Cambridge, MA; Institute for Stroke and Dementia Research (ISD) (R.M., M.D.), University Hospital, LMU Munich; Munich Cluster for Systems Neurology (SyNergy) (M.D.); German Center for Neurodegenerative Diseases (DZNE) (M.D.), Munich, Germany; Geriatric Research and Education Clinical Center (B.D.M., S.J.K.), Veterans Administration Medical Center, Baltimore, MD.
Article Synopsis
- The study investigates genetic variants linked to early-onset ischemic stroke (EOS) in individuals aged 18-59, contrasting with previous research focused on late-onset stroke (LOS).
- Researchers conducted a meta-analysis involving 16,730 EOS cases and 599,237 controls to identify significant genetic associations and compared results between EOS and LOS.
- Findings include two genetic variants associated with blood subgroups that show a stronger connection to EOS than LOS, indicating that genetic factors promoting blood clotting are particularly influential in early-onset cases.
Amniotic membrane conditioned medium (AMCM) reduces inflammatory response on human limbal myofibroblast, and the potential role of lumican.
Mol Vis
December 2021
Research Unit, Institute of Ophthalmology Conde de Valenciana Foundation, Mexico City, Mexico.
Purpose: Viral infections such as herpetic keratitis (HSK) activate the innate immune response in the cornea triggering opacity and loss of vision. This condition is performed mainly by myofibroblasts that exacerbate secretion of inflammatory cytokines. Amniotic membrane transplantation (AMT) reduces ocular opacity and scarring inhibiting secretion of inflammatory cytokines and proliferation of myofibroblasts.
View Article and Find Full Text PDFAn Optimized Informatics Pipeline for Mass Spectrometry-Based Peptidomics.
J Am Soc Mass Spectrom
December 2015
Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA, 99352, USA.
The comprehensive MS analysis of the peptidome, the intracellular and intercellular products of protein degradation, has the potential to provide novel insights on endogenous proteolytic processing and its utility in disease diagnosis and prognosis. Along with the advances in MS instrumentation and related platforms, a plethora of proteomics data analysis tools have been applied for direct use in peptidomics; however, an evaluation of the currently available informatics pipelines for peptidomics data analysis has yet to be reported. In this study, we began by evaluating the results of several popular MS/MS database search engines, including MS-GF+, SEQUEST, and MS-Align+, for peptidomics data analysis, followed by identification and label-free quantification using the well-established accurate mass and time (AMT) tag and newly developed informed quantification (IQ) approaches, both based on direct LC-MS analysis.
View Article and Find Full Text PDFIncreasing Confidence of LC-MS Identifications by Utilizing Ion Mobility Spectrometry.
Int J Mass Spectrom
November 2013
Pacific Northwest National Laboratory, Richland, WA 99352.
Ion mobility spectrometry in conjunction with liquid chromatography separations and mass spectrometry offers a range of new possibilities for analyzing complex biological samples. To fully utilize the information obtained from these three measurement dimensions, informatics tools based on the accurate mass and time tag methodology were modified to incorporate ion mobility spectrometry drift times for peptides observed in human serum. In this work a reference human serum database was created for 12,139 peptides and populated with the monoisotopic mass, liquid chromatography normalized elution time, and ion mobility spectrometry drift time(s) for each.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!